Search results for Reslizumab
Reslizumab, Abbexa, abx831156
Reslizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL5, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab inhibits IL-5-dependent cell proliferation, with an IC50 value of approximately 91. 1pM. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4. 3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Reslizumab Biosimilar - Research Grade, ichor.bio, ICH5272
Detects human IL5
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Research Grade Reslizumab (HY218016), abinScience, HY218016
Host
Humanized
Reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Conjugation
Please provide the required information below so that we can quickly source your products.